Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate

BACKGROUND: Targeted alpha therapy has been postulated to have great potential for the treatment of small clusters of tumour cells as well as small metastases. (213)Bismuth, an α-emitter with a half-life of 46 min, has shown to be effective in preclinical as well as in clinical applications. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Ho Sze, Konijnenberg, Mark W., de Blois, Erik, Koelewijn, Stuart, Baum, Richard P., Morgenstern, Alfred, Bruchertseifer, Frank, Breeman, Wouter A., de Jong, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720616/
https://www.ncbi.nlm.nih.gov/pubmed/26791386
http://dx.doi.org/10.1186/s13550-016-0162-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720616/
https://www.ncbi.nlm.nih.gov/pubmed/26791386
http://dx.doi.org/10.1186/s13550-016-0162-2

Ejemplares similares